Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

Inclusion Criteria:

• History of asthma attacks
• Taking inhaled corticosteroids
• Non-smoking

Exclusion Criteria:

• Women of child-bearing potential
• History of respiratory disease other than asthma
• History of severe allergy to food or drugs
• Previous use of monoclonal antibodies
• Very low or high body weight

Other protocol-defined inclusion/exclusion criteria may apply.